MedTrace Logo

Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

NCT02300753 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2014-11-25

No results posted yet for this study

Summary

Expanded access Protocol to treat LHON subjects with EPI743

Conditions

  • Leber's Hereditary Optic Neuropathy

Interventions

DRUG

EPI-743

EPI-743 is a quinone oxidation product of alpha-tocotrienol

Sponsors & Collaborators

  • Edison Pharmaceuticals Inc

    lead INDUSTRY

Eligibility

Min Age
8 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02300753 on ClinicalTrials.gov